Physiopathology of Phosphate Disorders

被引:12
作者
Portales-Castillo, Ignacio [1 ,2 ,3 ]
Rieg, Timo [4 ,5 ,6 ]
Khalid, Sheikh B. [7 ]
Nigwekar, Sagar U. [1 ,2 ]
Neyra, Javier A. [8 ]
机构
[1] Massachusetts Gen Hosp, Div Nephrol, Dept Med, Boston, MA USA
[2] Harvard Med Sch, Boston, MA USA
[3] Massachusetts Gen Hosp, Endocrine Unit, Boston, MA USA
[4] Univ S Florida, Dept Mol Pharmacol & Physiol, Tampa, FL USA
[5] James A Haley Vet Hosp, Tampa, FL USA
[6] Univ S Florida, Ctr Hypertens & Kidney Res, Tampa, FL USA
[7] Indus Hosp, Dept Internal Med, Lahore, Pakistan
[8] Univ Alabama Birmingham, Dept Internal Med, Div Nephrol, Birmingham, AL USA
来源
ADVANCES IN KIDNEY DISEASE AND HEALTH | 2023年 / 30卷 / 02期
关键词
CHRONIC KIDNEY-DISEASE; HEREDITARY HYPOPHOSPHATEMIC RICKETS; IRON-DEFICIENCY ANEMIA; VITAMIN-D-RECEPTOR; P-I COTRANSPORTER; GROWTH-FACTOR; 23; PARATHYROID-HORMONE; SERUM PHOSPHORUS; CARDIOVASCULAR-DISEASE; MAINTENANCE DIALYSIS;
D O I
10.1053/j.akdh.2022.12.011
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Intracellular phosphate is critical for cellular processes such as signaling, nucleic acid synthesis, and membrane function. Extra-cellular phosphate (Pi) is an important component of the skeleton. Normal levels of serum phosphate are maintained by the co-ordinated actions of 1,25-dihydroxyvitamin D3, parathyroid hormone and fibroblast growth factor-23, which intersect in the proximal tubule to control the reabsorption of phosphate via the sodium-phosphate cotransporters Npt2a and Npt2c. Further-more, 1,25-dihydroxyvitamin D3 participates in the regulation of dietary phosphate absorption in the small intestine. Clinical manifestations associated with abnormal serum phosphate levels are common and occur as a result of genetic or acquired con-ditions affecting phosphate homeostasis. For example, chronic hypophosphatemia leads to osteomalacia in adults and rickets in children. Acute severe hypophosphatemia can affect multiple organs leading to rhabdomyolysis, respiratory dysfunction, and hemolysis. Patients with impaired kidney function, such as those with advanced CKD, have high prevalence of hyperphospha-temia, with approximately two-thirds of patients on chronic hemodialysis in the United States having serum phosphate levels above the recommended goal of 5.5 mg/dL, a cutoff associated with excess risk of cardiovascular complications. Furthermore, patients with advanced kidney disease and hyperphosphatemia (>6.5 mg/dL) have almost one-third excess risk of death than those with phosphate levels between 2.4 and 6.5 mg/dL. Given the complex mechanisms that regulate phosphate levels, the interventions to treat the various diseases associated with hypophosphatemia or hyperphosphatemia rely on the understand -ing of the underlying pathobiological mechanisms governing each patient condition.& COPY; 2023 Published by Elsevier Inc. on behalf of the National Kidney Foundation, Inc.
引用
收藏
页码:177 / 188
页数:12
相关论文
共 92 条
[1]  
Bansal V.K., 1990, Clinical Methods: The History, Physical, and Laboratory Examinations, V3rd
[2]   The demonstration of αKlotho deficiency in human chronic kidney disease with a novel synthetic antibody [J].
Barker, Sarah L. ;
Pastor, Johanne ;
Carranza, Danielle ;
Quiones, Henry ;
Griffith, Carolyn ;
Goetz, Regina ;
Mohammadi, Moosa ;
Ye, Jianfeng ;
Zhang, Jianning ;
Hu, Ming Chang ;
Kuro-o, Makoto ;
Moe, Orson W. ;
Sidhu, Sachdev S. .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2015, 30 (02) :223-233
[3]   Targeted inactivation of Npt2 in mice leads to severe renal phosphate wasting, hypercalciuria, and skeletal abnormalities [J].
Beck, L ;
Karaplis, AC ;
Amizuka, N ;
Hewson, AS ;
Ozawa, H ;
Tenenhouse, HS .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (09) :5372-5377
[4]   An FGF23 missense mutation causes familial tumoral calcinosis with hyperphosphatemia [J].
Benet-Pagès, A ;
Orlik, P ;
Strom, TM ;
Lorenz-Depiereux, B .
HUMAN MOLECULAR GENETICS, 2005, 14 (03) :385-390
[5]   FGF23 is processed by proprotein convertases but not by PHEX [J].
Beret-Pagès, A ;
Lorenz-Depiereux, B ;
Zischka, H ;
White, KE ;
Econs, MJ ;
Strom, TM .
BONE, 2004, 35 (02) :455-462
[6]   Prevalence of hypophosphatemia in the ICU- Results of an international one-day point prevalence survey [J].
Berger, M. M. ;
Appelberg, O. ;
Reintam-Blaser, A. ;
Ichai, C. ;
Joannes-Boyau, O. ;
Casaer, M. ;
Schaller, S. J. ;
Gunst, J. ;
Starkopf, J. .
CLINICAL NUTRITION, 2021, 40 (05) :3615-3621
[7]   Hereditary hypophosphatemic rickets with hypercalciuria: pathophysiology, clinical presentation, diagnosis and therapy [J].
Bergwitz, Clemens ;
Miyamoto, Ken-Ichi .
PFLUGERS ARCHIV-EUROPEAN JOURNAL OF PHYSIOLOGY, 2019, 471 (01) :149-163
[8]   Regulation of Phosphate Homeostasis by PTH, Vitamin D, and FGF23 [J].
Bergwitz, Clemens ;
Jueppner, Harald .
ANNUAL REVIEW OF MEDICINE, 2010, 61 :91-104
[9]   Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: A national study [J].
Block, GA ;
Hulbert-Shearon, TE ;
Levin, NW ;
Port, FK .
AMERICAN JOURNAL OF KIDNEY DISEASES, 1998, 31 (04) :607-617
[10]   Safety and Efficacy of Tenapanor for Long-term Serum Phosphate Control in Maintenance Dialysis: A 52-Week Randomized Phase 3 Trial (PHREEDOM) [J].
Block, Geoffrey A. ;
Bleyer, Anthony J. ;
Silva, Arnold L. ;
Weiner, Daniel E. ;
Lynn, Robert, I ;
Yang, Yang ;
Rosenbaum, David P. ;
Chertow, Glenn M. .
KIDNEY360, 2021, 2 (10) :1600-1610